Levodopa/Carbidopa Ratiopharm

Levodopa, the active ingredient in Levodopa/Carbidopa Ratiopharm, is a dopamine precursor / dopa decarboxylase inhibitor combination presented as an oral tablet for oral use. It is used to treat Parkinson's disease and related Parkinsonian syndromes in adult patients.

GNH USA supplies Levodopa/Carbidopa Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier, providing quality‑assured medicines to hospitals, pharmacies and clinics worldwide. The company follows EU GMP standards to ensure product integrity.

Levodopa/Carbidopa is indicated for disorders of the dopaminergic system, primarily Parkinsonian conditions.

Parkinson's disease: improves motor function and reduces rigidity and bradykinesia. Parkinsonian syndrome: alleviates tremor, stiffness and movement difficulties. Levodopa‑responsive Parkinsonism: restores dopamine levels to improve daily activities.

Levodopa/Carbidopa may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea and vomiting - Orthostatic hypotension - Dizziness or light‑headedness - Headache - Insomnia - Dry mouth

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Psychiatric disturbances such as hallucinations or confusion - Severe hypotension or cardiac arrhythmias - Neuroleptic malignant‑like syndrome - Severe allergic reactions including anaphylaxis - Respiratory depression in extreme cases

When prescribing Levodopa/Carbidopa, clinicians should observe several precautionary measures to optimise safety.

Assess cardiovascular status: monitor blood pressure for orthostatic changes. Review psychiatric history: watch for hallucinations or mood swings. Evaluate renal and hepatic function: adjust if impairment present. Avoid abrupt discontinuation: taper to prevent withdrawal symptoms. Store below 25°C: keep in the original pack, protect from moisture.

Levodopa/Carbidopa interacts with several medicines that can alter its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Anticholinergic agents: may mask motor benefits. - High‑protein meals: reduce levodopa absorption. - Dopamine antagonists (e.g., antipsychotics): diminish therapeutic effect.

Moderate Interactions (Monitor Closely): - Selective MAO‑B inhibitors: may increase dopaminergic activity. - SSRIs and SNRIs: potential for serotonin syndrome. - Beta‑blockers: may exacerbate orthostatic hypotension.